Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0049-3848(80)90092-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Co-treatment With Aripiprazole and Vincristine Sensitizes P-Glycoprotein-Overexpressing Drug-resistant MCF-7/ADR Breast Cancer Cells.
Anticancer Res
March 2024
School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea;
Background/aim: Evidence supports that use of aripiprazole sensitizes drug-resistant oral cancer cells. The aim of the study was to investigate whether aripiprazole can achieve sensitization of highly drug-resistant breast cancer cells, as well as identify its relevant mechanisms of action.
Materials And Methods: MCF-7/ADR, KB, and KBV20C breast cancer cells were treated with aripiprazole, vincristine (VIC), vinorelbine, vinblastine and their combination.
High-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection.
Antiviral Res
February 2024
Department of Molecular and Biomedical Sciences, The University of Maine, Orono, ME, 04469, USA; Graduate School of Biomedical Science and Engineering, Orono, ME, 04469, USA. Electronic address:
JC polyomavirus (JCPyV) is a nonenveloped, double-stranded DNA virus that infects the majority of the population. Immunocompetent individuals harbor infection in their kidneys, while severe immunosuppression can result in JCPyV spread to the brain, causing the neurodegenerative disease progressive multifocal leukoencephalopathy (PML). Due to a lack of approved therapies to treat JCPyV and PML, the disease results in rapid deterioration, and is often fatal.
View Article and Find Full Text PDFCombined Structure- and Ligand-Based Approach for the Identification of Inhibitors of AcrAB-TolC in .
ACS Infect Dis
December 2023
Health and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5000, Australia.
The inhibition of efflux pumps is a promising approach to combating multidrug-resistant bacteria. We have developed a combined structure- and ligand-based model, using OpenEye software, for the identification of inhibitors of AcrB, the inner membrane protein component of the AcrAB-TolC efflux pump in . From a database of 1391 FDA-approved drugs, 23 compounds were selected to test for efflux inhibition in .
View Article and Find Full Text PDFCabozantinib Carries the Risk of Drug-Drug Interactions Inhibition of UDPglucuronosyltransferase (UGT) 1A9.
Curr Drug Metab
January 2023
School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin 124221, China.
Background: Cabozantinib is a multiple receptor tyrosine kinases inhibitor (TKI) approved to treat progressive, metastatic medullary thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma. Drugdrug interactions (DDIs) for cabozantinib have been identified involving the role of cytochromes P450. Although the previous study reported that cabozantinib showed a slight inhibition of UDP-glucuronosyltransferase (UGT) 1A1 at the highest concentration tested, there are no reports on the potential for UGTs-mediated-DDIs.
View Article and Find Full Text PDFThe endoplasmic reticulum membrane protein Sec62 as potential therapeutic target in overexpressing tumors.
Front Physiol
October 2022
Competence Center for Molecular Medicine, Saarland University, Homburg, Germany.
The human gene is located on chromosome 3q, was characterized as a tumor driver gene and is found to be overexpressed in an ever-growing number of tumors, particularly those with 3q26 amplification. Where analyzed, overexpression was associated with poor prognosis. Sec62 protein is a membrane protein of the endoplasmic reticulum (ER) and has functions in endoplasmic reticulum protein import, endoplasmic reticulum-phagy and -in cooperation with the cytosolic protein calmodulin- the maintenance of cellular calcium homeostasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!